Antibody drug conjugates: hitting the mark in pancreatic cancer?

Journal of Experimental & Clinical Cancer Research

Review

Nicole L. Wittwer¹  Vasilios Liapis¹  Alexander H. Staudacher¹  Michael P. Brown² 

[1] Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, 5000, Adelaide, SA, Australia;Adelaide Medical School, University of Adelaide, 5000, Adelaide, SA, Australia;Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, 5000, Adelaide, SA, Australia;Adelaide Medical School, University of Adelaide, 5000, Adelaide, SA, Australia;Cancer Clinical Trials Unit, Royal Adelaide Hospital, 5000, Adelaide, SA, Australia;

关键词: Pancreatic cancer;    Antibody drug conjugate;    Bystander killing;   

DOI  :  10.1186/s13046-023-02868-x

 received in 2023-06-05, accepted in 2023-10-16,  发布年份 2023

来源: Springer

【 摘 要 】

Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade. Late detection of the disease means that in most cases the disease has advanced locally and/or metastasized, and curative surgery is not possible. Chemotherapy is still the first-line treatment however, this has only had a modest impact in improving survival, with associated toxicities. Therefore, there is an urgent need for targeted approaches to better treat pancreatic cancer, while minimizing treatment-induced side-effects. Antibody drug conjugates (ADCs) are one treatment option that could fill this gap. Here, a monoclonal antibody is used to deliver extremely potent drugs directly to the tumor site to improve on-target killing while reducing off-target toxicity. In this paper, we review the current literature for ADC targets that have been examined in vivo for treating pancreatic cancer, summarize current and on-going clinical trials using ADCs to treat pancreatic cancer and discuss potential strategies to improve their therapeutic window.

【 授权许可】

CC BY   
© Italian National Cancer Institute ‘Regina Elena’ 2023

【 图 表 】

12951_2015_155_Article_IEq14.gif

12951_2015_155_Article_IEq9.gif